Abstract
Pancreatic cancer has a dismal prognosis. A technically perfect surgical operation may still not provide a survival advantage for patients with technically resectable pancreatic cancer. Appropriate selection of patients for surgical resections is an imminent issue. Recent studies have provided an important clue on what serum biomarkers may be used to select out the patients who would unlikely benefit from the surgical resection.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 360-362 |
| Number of pages | 3 |
| Journal | Cancer Biology and Therapy |
| Volume | 16 |
| Issue number | 3 |
| DOIs |
|
| State | Published - Mar 1 2015 |
| Externally published | Yes |
ASJC Scopus subject areas
- Molecular Medicine
- Oncology
- Pharmacology
- Cancer Research
Fingerprint
Dive into the research topics of 'Which patients with resectable pancreatic cancer truly benefit from oncological resection: Is it destiny or biology?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS